BCL2 interacting protein 3 pseudogene 38 (BNIP3P38)

BCL2 interacting protein 3 pseudogene 38 (BNIP3P38) is classified as a pseudogene, meaning it is a genomic DNA sequence similar to a known gene but is generally non-functional for protein coding and is not considered an RNA or protein target for therapeutic intervention[1][3]. Pseudogenes may have regulatory roles at the RNA level, for example by acting as decoys for microRNAs or being processed into small RNAs that influence gene expression[4][6]. BNIP3P38 is related by sequence to the BNIP3 gene, which is a proapoptotic member of the BCL2 protein family, but there is no evidence that BNIP3P38 codes for a functional protein or serves as a receptor, enzyme, or other canonical drug target[1][3]. Pseudogenes like BNIP3P38 are not generally tractable as drug targets, but ongoing research explores potential non-coding RNA roles in development or disease, though specific functions for this pseudogene have not been established[2][4][6]. Important context: - No evidence links BNIP3P38 to drug interactions, targetable molecular mechanisms, or clinical disease roles as a canonical biomarker or safety concern[1][3][4][6]. - As a pseudogene, BNIP3P38 should not be considered a typical molecular target for therapeutic development[1][3]. - The entry is not incorrect in sequence or nomenclature, but it is incorrect if queried as a "therapeutic target," "receptor," or related tractable protein, as it does not fulfill these criteria[1][3]. For further study, distinguishing functional pseudogenes from non-functional genomic sequences remains an evolving research area[2][4][6].

Other names

BCL2/adenovirus E1B 19kDa interacting protein 3 pseudogene 38BNIP3P38